Super Drugs for Super Bugs

ESBL and carbapenemase-producing gram negatives now show up in everyday emergency care, especially in nursing-home residents, recently hospitalized patients, and those with devices. Empiric choices for urosepsis and resistant Pseudomonas hinge on exposure history, local antibiograms, and knowing when a positive culture does not need treatment.

ESBL and Carbapenemase Infections

• ESBL resistance mechanism: Extended-spectrum beta-lactamases hydrolyze most cephalosporins and often travel on plasmids, which helps resistance spread quickly across Enterobacteriaceae.
• High-risk exposure pattern: Recent hospitalization or ICU stay, long-term care residence, foreign bodies, prior antibiotics, hemodialysis, and ventilation sharply raise the pretest probability of ESBL infection.
• Empiric urosepsis choice: Carbapenems remain the best-studied first-line agents for ESBL urosepsis, while piperacillin-tazobactam is not a reliable fallback even when the lab reports susceptibility.
• Collateral resistance problem: ESBL isolates are frequently co-resistant to fluoroquinolones and TMP-SMX, making familiar oral step-down options far less dependable at the bedside.
• Carbapenemase escalation: Carbapenemases knock out even carbapenems and can leave only agents like ceftazidime-avibactam or meropenem-vaborbactam, with combination nuances we get into in the episode.
• Positive culture context: Not every culture growing a multidrug-resistant organism needs admission or treatment; a chronically colonized Foley urine is often positive without true infection.

Resistant Pseudomonas and Outpatient Options

• Pseudomonas risk profile: Sepsis with skilled-nursing exposure, prior surgery, prolonged antibiotic courses, neutropenia, burns, and long lengths of stay should push resistant Pseudomonas higher on the list.
• Antipseudomonal drug reality: Cefepime, ceftazidime, piperacillin-tazobactam, aztreonam, ciprofloxacin, aminoglycosides, and meropenem all face meaningful resistance pressure, so no single class is fail-safe.
• Combination therapy rationale: Using two antipseudomonal agents from different classes can improve the odds that at least one is active when multidrug resistance is a real concern. We walk through when that matters on the show.
• Local epidemiology matters: Resistance patterns vary by hospital and unit, so the local antibiogram and early infectious-disease input often matter more than any generic national preference list.
• Selective outpatient management: Some ESBL urinary infections can be managed outside the hospital, and some bacteriuria should be left alone entirely if the patient lacks symptoms of true infection.
• Oral cystitis options: Nitrofurantoin and fosfomycin remain useful oral options for ESBL cystitis, but nitrofurantoin is not a pyelonephritis drug and oral strategies have important caveats in the chapter.

References:

1. Talan DA, et al. Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States. Ann Emerg Med. 2021;77(1):32-43. PMID: 33131912
2. Weiner LM, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016;37(11):1288-1301. PMID: 27573805
3. Hatlen TJ, et al. Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. J Antimicrob Chemother. 2020;75(7):1993-1997. PMID: 32303061
4. Bader MS, et al. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020;132(3):234-250. PMID: 31608743